The Hong Kong Joint Oncology Centre is now recruiting patients with resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) to participate in the Phase 3 clinical study NCT06312137, using Pembrolizumab combined with MK-2870 treatment, with free medication and imaging scanning fees. Get in touch with us immediately to inquire about eligibility, research process, and risks.